Cardiol Therapeutics (CRDL) Interest & Investment Income (2020 - 2026)
Cardiol Therapeutics (CRDL) posted Interest & Investment Income of $146369.1 for Q1 2026, up 16.5% on a QoQ basis from $125640.0 in Q4 2025, and down 15.4% year-over-year from $173022.8 in Q1 2025.
Cardiol Therapeutics (CRDL) Interest & Investment Income (2020 - 2026) Analysis & Trends
Cardiol Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $146369.1 for Q1 2026.
- Quarterly Interest & Investment Income fell 15.4% year-over-year to $146369.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $491234.2 (down 35.82% YoY) and the FY2025 annual result came in at $520892.2, down 39.02% from the prior year.
- Interest & Investment Income was $146369.1 for Q1 2026 at Cardiol Therapeutics, up from $125640.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $430711.2 in Q4 2022 and bottomed at $57087.8 in Q1 2022.
- A 5-year average of $234367.5 and a median of $219604.6 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1855.24% — and 2024, when it sank 61.52%.
- Cardiol Therapeutics' Interest & Investment Income stood at $430711.2 in 2022, then retreated by 23.55% to $329294.5 in 2023, then slumped by 33.31% to $219604.6 in 2024, then sank by 42.79% to $125640.0 in 2025, then advanced by 16.5% to $146369.1 in 2026.
- Business Quant data shows CRDL's Interest & Investment Income at $146369.1 in Q1 2026, $125640.0 in Q4 2025, and $88835.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Cardiol Therapeutics | 126.97 Mn | 126.97 Mn | - | 146,369.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146,369.08 |
| Dec 31, 2025 | 125,639.97 |
| Sep 30, 2025 | 88,835.49 |
| Jun 30, 2025 | 130,389.63 |
| Mar 31, 2025 | 173,022.76 |
| Dec 31, 2024 | 219,604.62 |
| Sep 30, 2024 | 147,977.09 |
| Jun 30, 2024 | 224,759.18 |
| Mar 31, 2024 | 279,994.86 |
| Dec 31, 2023 | 329,294.48 |
| Sep 30, 2023 | 384,555.50 |
| Jun 30, 2023 | 393,589.78 |
| Mar 31, 2023 | 403,820.22 |
| Dec 31, 2022 | 430,711.16 |
| Sep 30, 2022 | 298,523.45 |
| Jun 30, 2022 | 150,072.60 |
| Mar 31, 2022 | 57,087.76 |
| Dec 31, 2021 | 22,028.56 |
| Sep 30, 2021 | 28,543.13 |
| Jun 30, 2021 | 20,728.67 |